Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q1
Sell
-80,000
Closed -$2.43M 3574
2017
Q4
$2.43M Sell
80,000
-100
-0.1% -$2.66K ﹤0.01% 1998
2017
Q3
$1.94M Hold
80,100
﹤0.01% 2048
2017
Q2
$1.97M Hold
80,100
﹤0.01% 1988
2017
Q1
$1.74M Sell
80,100
-2,500
-3% -$50.8K ﹤0.01% 1931
2016
Q4
$1.23M Sell
82,600
-37,400
-31% -$540K ﹤0.01% 2329
2016
Q3
$1.53M Buy
120,000
+70,000
+140% +$757K ﹤0.01% 2112
2016
Q2
$391K Buy
+50,000
New +$288K ﹤0.01% 2900

Other funds holding EXEL

David Shaw's EXEL Position: Q2 2026 in Review

David Shaw increased its Exelixis (EXEL) stake by 54% in Q2 2026, buying an estimated $94.9M and bringing the position to 5,551,747 shares worth $302M. The position accounts for 0.14% of the portfolio, ranked #131.

David Shaw first reported a position in EXEL in Q2 2013 and has held it in 51 quarters since. 753 funds tracked by Wall St. Rank hold EXEL as of Q2 2026.

  • David Shaw held 5,551,747 shares of Exelixis worth $302M as of Q2 2026.
  • David Shaw bought 1,948,684 Exelixis shares in Q2 2026, an estimated $94.9M.
  • Exelixis made up 0.14% of David Shaw's portfolio in Q2 2026, its #131 holding.
  • David Shaw first reported a position in Exelixis in Q2 2013 and has held it in 51 quarters since.
  • 753 funds tracked by Wall St. Rank held Exelixis as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.